Company intelligence / Profile preview

Vitacam

Ownership: Private
Development stage: Commercial

Overview

Vitacam has demonstrated accurate contactless measurement of respiratory rate (+/- 3 per min) and pulse (+/- 5 bpm), validated through collaborations with teaching hospitals/universities in Finland and the UK. It is CE marked as a Class IIa medical device. Early pilots show promise for improving workflow efficiency, especially for elderly/home care patients. Health economic modeling suggests potential cost-effectiveness for atrial fibrillation screening.

Therapeutic areas: Cardiovascular
Modalities: DeviceSoftware-based medical device
Industry: Physiological Monitoring

Partnerships

Oulu University Hospital (Finland) [clinical collaboration/development partner]Academic collaborations with several teaching hospitals/universities in Finland & UK were crucial to development/validation.Customers include Faizan Global Relief Fund & Taivalkosken Kunta.

Beyond the preview

Go deeper on Vitacam.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitacam.

Explore the full profile